Bli medlem
Bli medlem

Du är här

2014-05-13

AstraZeneca: STATEMENT REGARDING PFIZER ANNOUNCEMENT

The Board of AstraZeneca PLC ("AstraZeneca") notes the announcement
made by Pfizer Inc. ("Pfizer") earlier today. Pfizer's announcement
contains no new proposal nor substantive new information.

The Board of AstraZeneca believes Pfizer is making an opportunistic
attempt to acquire a transformed AstraZeneca, without reflecting the
value of its exciting pipeline. This value should accrue fully to
AstraZeneca shareholders.

The Board reiterates its confidence in AstraZeneca's ability to
deliver on its prospects as an independent, science led business.

A copy of this announcement will be available on AstraZeneca's website
at www.astrazeneca.com.

- ENDS -

NOTES TO EDITORS

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business
that focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of
cardiovascular, metabolic, respiratory, inflammation, autoimmune,
oncology, infection and neuroscience diseases. AstraZeneca operates
in over 100 countries and its innovative medicines are used by
millions of patients worldwide. For more information please visit:
www.astrazeneca.com

AstraZeneca Enquiries

Investor Relations:

Karl Hård (London) +44 20 7604 8123

Colleen Proctor (US) +1 302 886 1842

Jens Lindberg (London) +44 20 7604 8414

Anthony Brown (London) +44 20 7604 8067

Corporate Communications:

Esra Erkal-Paler +44 20 7604 8030

Ayesha Bharmal +44 20 7604 8034

Vanessa Rhodes +44 20 7604 8037

RLM Finsbury

Conor McClafferty + 44 20 7251 3801

Adviser Enquiries

Robey Warshaw: Simon Robey +44 20 7317 3900

Simon Warshaw

Evercore Partners: Francois Maisonrouge +1 212 857 3100

Goldman Sachs: Karen Cook +44 20 7774 1000

Phil Raper (Corporate Broking)

Morgan Stanley: Colm Donlon +44 20 7425 8000

Andrew Foster (Corporate Broking)

Further Information

Robey Warshaw LLP, which is authorised and regulated in the United
Kingdom by the Financial Conduct Authority, is acting as financial
adviser exclusively for AstraZeneca and no one else in connection
with the matters referred to in this announcement and will not regard
any other person as its client in relation to the matters referred to
in this announcement and will not be responsible to anyone other than
AstraZeneca for providing the protections afforded to clients of
Robey Warshaw LLP, nor for providing advice in relation to the
matters referred to in this announcement.

Evercore Partners International LLP, which is authorised and regulated
in the United Kingdom by the Financial Conduct Authority, is acting
as financial adviser exclusively for AstraZeneca and no one else in
connection with the matters referred to in this announcement and will
not regard any other person as its client in relation to the matters
referred to in this announcement and will not be responsible to
anyone other than AstraZeneca for providing the protections afforded
to clients of Evercore Partners International LLP, nor for providing
advice in relation to the matters referred to in this announcement.

Goldman Sachs International, which is authorised by the Prudential
Regulation Authority and regulated by the Financial Conduct Authority
and the Prudential Regulation Authority in the United Kingdom, is
acting exclusively for AstraZeneca and no one else in connection with
the matters referred to in this announcement and will not be
responsible to anyone other than AstraZeneca for providing the
protections afforded to clients of Goldman Sachs International, or
for providing advice in connection with the matters referred to in
this announcement.

Morgan Stanley & Co. International plc, which is authorised by the
Prudential Regulation Authority and regulated by the Financial
Conduct Authority and the Prudential Regulation Authority in the
United Kingdom, is acting as financial adviser to AstraZeneca, and no
one else in connection with the matters referred to in this
announcement. In connection with such matters, Morgan Stanley & Co.
International plc, its affiliates and its and their respective
directors, officers, employees and agents will not regard any other
person as their client, nor will they be responsible to any other
person other than AstraZeneca for providing the protections afforded
to their clients or for providing advice in connection with the
contents of this announcement or any other matter referred to herein.

Dealing Disclosure Requirements

Under Rule 8.3(a) of the Code, any person who is interested in 1% or
more of any class of relevant securities of an offeree company or of
any securities exchange offeror (being any offeror other than an
offeror in respect of which it has been announced that its offer is,
or is likely to be, solely in cash) must make an Opening Position
Disclosure following the commencement of the offer period and, if
later, following the announcement in which any securities exchange
offeror is first identified. An Opening Position Disclosure must
contain details of the person's interests and short positions in, and
rights to subscribe for, any relevant securities of each of (i) the
offeree company and (ii) any securities exchange offeror(s). An
Opening Position Disclosure by a person to whom Rule 8.3(a) applies
must be made by no later than 3.30 pm (London time) on the 10th
business day following the commencement of the offer period and, if
appropriate, by no later than 3.30 pm (London time) on the 10th
business day following the announcement in which any securities
exchange offeror is first identified. Relevant persons who deal in
the relevant securities of the offeree company or of a securities
exchange offeror prior to the deadline for making an Opening Position
Disclosure must instead make a Dealing Disclosure.

Under Rule 8.3(b) of the Code, any person who is, or becomes,
interested in 1% or more of any class of relevant securities of the
offeree company or of any securities exchange offeror must make a
Dealing Disclosure if the person deals in any relevant securities of
the offeree company or of any securities exchange offeror. A Dealing
Disclosure must contain details of the dealing concerned and of the
person's interests and short positions in, and rights to subscribe
for, any relevant securities of each of (i) the offeree company and
(ii) any securities exchange offeror, save to the extent that these
details have previously been disclosed under Rule 8. A Dealing
Disclosure by a person to whom Rule 8.3(b) applies must be made by no
later than 3.30 pm (London time) on the business day following the
date of the relevant dealing.

If two or more persons act together pursuant to an agreement or
understanding, whether formal or informal, to acquire or control an
interest in relevant securities of an offeree company or a securities
exchange offeror, they will be deemed to be a single person for the
purpose of Rule 8.3.

Opening Position Disclosures must also be made by the offeree company
and by any offeror and Dealing Disclosures must also be made by the
offeree company, by any offeror and by any persons acting in concert
with any of them (see Rules 8.1, 8.2 and 8.4).

Details of the offeree and offeror companies in respect of whose
relevant securities Opening Position Disclosures and Dealing
Disclosures must be made can be found in the Disclosure Table on the
Takeover Panel's website at www.thetakeoverpanel.org.uk, including
details of the number of relevant securities in issue, when the offer
period commenced and when any offeror was first identified. You
should contact the Panel's Market Surveillance Unit on +44 (0)20 7638
0129 if you are in any doubt as to whether you are required to make
an Opening Position Disclosure or a Dealing Disclosure.

Forward-Looking Statements

This announcement (including information incorporated by reference in
this announcement), oral statements made regarding the Proposal, and
other information published by AstraZeneca contain statements which
are, or may be deemed to be, "forward-looking statements", including
for the purposes of the US Private Securities Litigation Reform Act
of 1995. Forward-looking statements are prospective in nature and are
not based on historical facts, but rather on current expectations and
projections of the management of AstraZeneca about future events, and
are therefore subject to risks and uncertainties which could cause
actual results to differ materially from the future results expressed
or implied by the forward-looking statements. Often, but not always,
forward-looking statements can be identified by the use of
forward-looking words such as "plans", "expects" or "does not
expect", "is expected", "is subject to", "budget", "scheduled",
"estimates", "forecasts", "intends", "anticipates" or "does not
anticipate", or "believes", or variations of such words and phrases
or statements that certain actions, events or results "may", "could",
"should", "would", "might" or "will" be taken, occur or be achieved.
Although AstraZeneca believes that the expectations reflected in such
forward-looking statements are reasonable, AstraZeneca can give no
assurance that such expectations will prove to be correct. By their
nature, forward-looking statements involve risk and uncertainty
because they relate to events and depend on circumstances that will
occur in the future. There are a number of factors that could cause
actual results and developments to differ materially from those
expressed or implied by such forward-looking statements. These
factors include the loss or expiration of patents, marketing
exclusivity or trademarks, or the risk of failure to obtain patent
protection; the risk of substantial adverse litigation/government
investigation claims and insufficient insurance coverage; exchange
rate fluctuations; the risk that R&D will not yield new products that
achieve commercial success; the risk that strategic alliances and
acquisitions will be unsuccessful; the impact of competition, price
controls and price reductions; taxation risks; the risk of
substantial product liability claims; the impact of any delays in the
manufacturing, distribution and sa...

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.